Invalidity dossier
US 3136815
Amino substituted benzophenone oximes and derivatives thereof
Current assignee: F Hoffmann La Roche AG
Added 9/23/2026, 5:20:07 PM
Active provider: DeepSeek · deepseek-v4-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US 3,136,815
Title: Amino substituted benzophenone oximes and derivatives thereof
Assignee/Current Assignee (per listing): F. Hoffmann-La Roche AG; Hoffmann La Roche Inc. Inventors: Reeder Earl; Sternbach Leo Henryk.
Key dates: Priority date 1959-12-10 (from US85859759); external priority also claimed from CH1349460A (1960-12-02); application US149527A filed 1961-11-02; published/granted 1964-06-09; anticipated expiration 1981-06-09; status "Expired – Lifetime." Legal status and priority dates are expressly noted in the source as assumptions, not legal conclusions.
Purpose and scope (plain language, from the supplied text): The patent concerns novel 5-aryl-3H-1,4-benzodiazepin-2(1H)-ones (Formula II), related compounds (Formulas I–V), and their 4,5-dihydro derivatives. Substituent definitions are given: R is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aralkyl, hydroxy-lower alkyl, or cyano-lower alkyl; R′ is hydrogen, lower alkyl, lower alkoxy-lower alkyl, phenyl, or hydroxybenzyl; R², R³ and R⁴ are hydrogen, halogen, or lower alkyl; R⁵ is hydrogen, lower alkyl, lower alkenyl, or lower alkynyl.
The text states these basic compounds form pharmaceutically acceptable acid addition salts with inorganic and organic acids, and that compounds with a tertiary amino nitrogen at the 4-position (Formula V, R other than hydrogen) form pharmaceutically acceptable quaternary ammonium salts with conventional quaternizing agents such as lower alkyl halides.
Synthesis described: reacting a 2-aminobenzophenone with hydroxylamine to form the oxime, then acylating with an α-halo-lower alkanoyl halide in the presence of base to yield a 2-(α-halo-lower alkanoylamino)-benzophenone oxime, which with one mole of base gives the 4-oxide (Formula II); alternative routes include acid-mediated cyclization to a 2-halomethyl-4-phenyl-quinazoline 3-oxide, reduction with phosphorus trichloride or hydrogen/Raney nickel, acid treatment of a 2-(N-methylacetamido) intermediate, and reaction with ammonia in alcoholic solution.
Not established by this excerpt: No claims are quoted, so exact claim scope is not shown. The excerpt omits portions of the specification (it is marked as excerpted), does not state utilities, dosages, or pharmacological data, and does not establish enablement, validity, or the accuracy of the listed classifications, assignees, or legal status.
Generated 10/1/2026, 9:43:40 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 3136815. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.